文献速递心境障碍

胰高血糖素样肽-1受体激动剂用于心境障碍与自杀风险

Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk.
PubMed 文献 · Biol Psychiatry · 2026-04-30

该综述汇总临床前、转化、观察性与临床数据,指出GLP-1RAs对心境障碍具潜在治疗价值,机制涉及代谢效应及神经可塑性、神经发生、神经保护等非互斥靶点。证据支持在重性抑郁障碍和双相障碍中开展充分对照的急性或维持治疗临床研究。自杀倾向与GLP-1RAs的关联已有报告,但因果关系尚未确立,初步证据提示其可能改善奖赏等病理维度并潜在影响自杀倾向。

要点

  • GLP-1RAs有望成为心境障碍的机制导向治疗,需在MDD和双相障碍中开展充分对照研究。
  • 其作用机制除代谢效应外,还涉及神经可塑性、神经发生、神经保护及自噬等非互斥靶点。
  • GLP-1RAs与自杀倾向的关联已有报告但因果关系未确立,初步证据提示可能通过奖赏维度产生益处。

核心结论

  • 现有证据提示GLP-1RAs是心境障碍有前景的机制导向治疗,支持在重性抑郁障碍和双相障碍中启动充分对照的临床研究。
  • GLP-1RAs与自杀倾向的关联已有报告但因果关系尚未确立。

研究设计与样本

  • 综述汇总临床前、转化、观察性和临床数据,评估GLP-1RAs用于心境障碍的潜力。

主要发现

  • GLP-1RAs的潜在作用机制涉及代谢效应以及神经可塑性、神经发生、神经分化、神经保护、抗凋亡和自噬等非互斥靶点。
  • 初步证据提示GLP-1RAs可能改善心境障碍中奖赏等病理维度,并可能对自杀倾向的某些方面产生潜在益处。

关键数值与推荐

  • 证据支持在重性抑郁障碍和双相障碍中开展GLP-1RAs作为急性或维持治疗的充分且良好对照的临床研究。

临床怎么用

  • 精神心理科医生可关注GLP-1RAs作为心境障碍潜在治疗的研究进展,但目前不应将其作为心境障碍或自杀风险的常规治疗推荐。

局限性

  • GLP-1RAs与自杀倾向的因果关系尚未确立,相关证据主要为观察性关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying innovative mechanisms that translate into improved therapeutics when compared to the extant options is a strategic imperative in mood disorders. More specifically, there is a need for treatments with greater efficacy, shorter time-to-peak efficacy, greater durability of effect, and improved tolerability profiles. Moreover, priority has also shifted toward identifying mood disorder therapeutics capable of targeting domains of psychopathology that are most pervasive, debilitating, and inadequately treated by conventional pharmacology (e.g., anhedonia and cognitive impairment). Available preclinical, translational, observational, and clinical data suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) hold promise as potentially mechanistically informed therapeutics for people with mood disorders. Although metabolic effectors are implicated as a putative mechanism of action of GLP-1RAs, nonmutually exclusive targets also include direct effects on neuroplasticity, neurogenesis, neurodifferentiation, neuroprotection, antiapoptotic, and autophagy mechanisms. Available evidence supports the initiation of adequate and well-controlled clinical studies in both major depressive disorder and bipolar disorder as acute and/or maintenance treatments. Although associations between suicidality and GLP-1RAs have been reported, causality has not been established. Moreover, preliminary evidence suggests that GLP-1RAs may benefit aspects of mood disorder psychopathology (e.g., reward) that may be predictive of potential beneficial effects on aspects of suicidality.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. McIntyre RS. Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk. Biol Psychiatry. 2026. PMID: 42069105. doi:10.1016/j.biopsych.2026.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。